Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma[4][5] and glioma.[6][7] It is a MEK inhibitor drug with anti-cancer activity.[8] It inhibits MEK1 and MEK2.[8] It is taken by mouth.[4][5]
The most common side effects include rash, diarrhea, tiredness, peripheral edema (swelling, especially of ankles and feet), nausea and acneiform dermatitis (acne-like inflammation of the skin).[5] When taken in combination with dabrafenib the most common side effects include fever, tiredness, nausea, chills, headache, diarrhea, vomiting, joint pain and rash.[5]
In May 2013, trametinib was approved as a single-agent by the US Food and Drug Administration for the treatment of people with V600E mutated metastatic melanoma.[9][10] It was approved for medical use in the European Union in June 2014.[5]
^"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
^"Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
^"Regulatory Decision Summary for Mekinist". Drug and Health Products Portal. 24 July 2023. Retrieved 2 April 2024.
^ abc"Mekinist- trametinib tablet, film coated". DailyMed. 22 June 2022. Archived from the original on 26 November 2022. Retrieved 3 January 2023.
^ abcdef"Mekinist EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 9 August 2021. Retrieved 27 February 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ ab"Spexotras Product information". Union Register of medicinal products. 8 January 2024. Retrieved 14 January 2024.
^ ab"Spexotras EPAR". European Medicines Agency. 9 November 2023. Retrieved 14 January 2024.
^ ab"Trametinib". NCI Drug Dictionary. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Archived from the original on 3 January 2023. Retrieved 28 February 2023. This article incorporates text from this source, which is in the public domain.
^"Drug Approval Package: Mekinist (trametinib) Tablets NDA #204114". U.S. Food and Drug Administration (FDA). 8 July 2013. Archived from the original on 27 October 2022. Retrieved 27 February 2023.
^"GSK melanoma drugs add to tally of U.S. drug approvals". Reuters. 30 May 2013. Archived from the original on 24 September 2015. Retrieved 5 July 2021.
Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma and glioma. It is a MEK inhibitor...
rash, joint pain, fever and tiredness. When taken in combination with trametinib, the most common side effects include fever, tiredness, nausea, chills...
BRAF inhibitors, such as vemurafenib and dabrafenib and a MEK inhibitor trametinib are the most effective, approved treatments for BRAF positive melanoma...
evaluated as a combination treatment against solid tumors together with trametinib in a clinical trial sponsored by the National Cancer Institute. In this...
include uveal melanoma (failed), and differentiated thyroid carcinoma. Trametinib (GSK1120212), FDA-approved to treat BRAF-mutated melanoma. Also studied...
of NSCLC) can be treated by dabrafenib combined with the MEK inhibitor trametinib; those with activated ROS1 (around 1% of NSCLC) can be inhibited by crizotinib...
BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor trametinib. Important prognosis factors for nodular melanoma include: Thickness Ulceration...
BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor trametinib. When arising in the nailbed of a digit, the evidence suggests that digit-sparing...
metastatic melanoma that harbors BRAF V600E mutation MEK inhibitors (trametinib, MEK162) are used in experiments, often in combination with BRAF inhibitors...
approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation". FDA. "Trametinib". Drug Bank. Retrieved 2023-10-24...
BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor trametinib. In February 2024, the Food and Drug Administration approved the first...
trial results compared vemurafenib with the combination of dabrafenib and trametinib for metastatic melanoma. Vemurafenib was approved in the United States...
thyroid cancer harboring such mutations. The combination of dabrafenib and trametinib has shown significant increases in overall survival and has been approved...
including Octreotide, Sirolimus, Anti-plasmin and, at least in one case, Trametinib. Dog breeds commonly affected by lymphangiectasia and/or protein-losing...
ALK inhibitors with MEK inhibitors: brigatinib+binimetinib, ceritinib+trametinib, and alectinib+cobimetinib. Results for the last two are expected around...
inhibitors, such as vemurafenib and dabrafenib; and an MEK inhibitor trametinib. Melanoma List of cutaneous conditions James, William D.; Berger, Timothy...
Novartis Pharmaceuticals melanoma with BRAF V600E or V600K mutations Trametinib Novartis Pharmaceuticals melanoma with BRAF V600E or V600K mutations Dabrafenib...
interstellar comet 2I/Borisov. 30 September – By combining doses of lithium, trametinib and rapamycin into a single treatment, researchers extend the lifespan...
including Octreotide, Sirolimus, Anti-plasmin and, at least in one case, Trametinib. The disease was first reported in 1961 by T.A. Waldmann. He described...
human patients with a kidney disease. By combining doses of lithium, trametinib and rapamycin into a single treatment, researchers extend the lifespan...
Global Information
This article incorporates text from this source, which is in the public domain.
